Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
ASH 2017 - Chronic Lymphocytic Leukemia
ASH 2017 - Chronic Lymphocytic Leukemia
Acalabrutinib Monotherapy in Patients with Relapsed/Refractory CLL: Updated Results from the Phase 1/2 ACE-CL-001 Study
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Long-Term Follow-Up of ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel in Patients with Refractory, Aggressive NHL
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Phase 2 Study of Brentuximab Vedotin plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Economic Evaluation for the United States of Ibrutinib versus Allogeneic HSCT for Patients with Relapsed or Refractory CLL with 17p Deletion
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or CLL
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Median 3.5-Year Follow-Up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle-Cell Lymphoma: A Pooled Analysis
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Comparison of Costs and Healthcare Resource Utilization in Patients with CLL Treated with Frontline Ibrutinib or Chemoimmunotherapy
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Preliminary Results of Prophylactic Tocilizumab After Axicabtagene Ciloleucel (axi-cel; KTE-C19) Treatment for Patients with Relapsed/Refractory, Aggressive NHL
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Single-Agent Ibrutinib versus Chemoimmunotherapy Regimens for Treatment-Naïve Patients with CLL: A Cross-Trial Comparison
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Prolonged Improvement in PROs and Well-Being in Older Patients with Treatment-Naïve CLL Treated with Ibrutinib: 3-Year Follow-Up of the RESONATE-2 Study
Read More
1
2
Page 2 of 2
Results 11 - 20 of 20